screened and identified a 3-thio-1,2,4-triazole derivative YUKA1 (Fig. 8, 41) as a KDM5A inhibitor with an in vitro IC50 value of 2.66 ± 0.69 μM, this compound reduced gefitinib- and trastuzumab-induced drug tolerance in EGFR-mutant lung cancer cells and HER2 + breast cancer cells, respectively [92]. Here, KDM5A is linked to breast carcinoma.